keyword
MENU ▼
Read by QxMD icon Read
search

HDL HIV

keyword
https://www.readbyqxmd.com/read/28121706/greater-remnant-lipoprotein-cholesterol-reduction-with-pitavastatin-compared-to-pravastatin-in-hiv-infected-patients-the-intrepid-trial
#1
Parag H Joshi, P Elliott Miller, Seth S Martin, Steven R Jones, Joseph M Massaro, Ralph B D'Agostino, Krishnaji R Kulkarni, Craig Sponseller, Peter P Toth
OBJECTIVE: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in those with HIV. An emerging CVD risk factor is triglyceride-rich remnant lipoprotein cholesterol (RLP-C: the sum of intermediate-density lipoprotein and very low-density lipoprotein3 cholesterol). The effects of statin therapy on lipoprotein subfractions, including RLP-C, in HIV-dyslipidemia are unknown. METHODS: This is a post-hoc analysis of the randomized INTREPID trial (NCT 01301066) comparing pitavastatin 4 mg daily vs...
January 24, 2017: AIDS
https://www.readbyqxmd.com/read/28107484/resveratrol-co-treatment-attenuates-the-effects-of-hiv-protease-inhibitors-on-rat-body-weight-and-enhances-cardiac-mitochondrial-respiration
#2
Burger Symington, Rudo F Mapanga, Gavin R Norton, M Faadiel Essop
Since the early 1990s human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) emerged as a global health pandemic, with sub-Saharan Africa the hardest hit. While the successful roll-out of antiretroviral (ARV) therapy provided significant relief to HIV-positive individuals, such treatment can also elicit damaging side-effects. Here especially HIV protease inhibitors (PIs) are implicated in the onset of cardio-metabolic complications such as type-2 diabetes and coronary heart disease. As there is a paucity of data regarding suitable co-treatments within this context, this preclinical study investigated whether resveratrol (RSV), aspirin (ASP) or vitamin C (VitC) co-treatment is able to blunt side-effects in a rat model of chronic PI exposure (Lopinavir/Ritonavir treatment for 4 months)...
2017: PloS One
https://www.readbyqxmd.com/read/28011249/lack-of-effects-of-statins-on-high-density-lipoprotein-subfractions-in-hiv-1-infected-patients-receiving-protease-inhibitors
#3
Randa Bittar, Élisabeth Aslangul, Philippe Giral, Lambert Assoumou, Marc-Antoine Valantin, Olga Kalmykova, Marie-Christine Federspiel, Corinne Cherfils, Dominique Costagliola, Dominique Bonnefont-Rousselot
BACKGROUND: We evaluated the effect of 45 days of rosuvastatin or pravastatin treatment on the distribution of HDL subfractions in HIV-1-infected individuals receiving boosted protease inhibitors (PIs) with cardiovascular risk. METHODS: The distribution of HDL subclasses by gradient gel electrophoresis was blindly assessed in 74 HIV-1-infected individuals receiving boosted PIs at baseline and at day 45 of statin treatment, and compared with the distribution obtained in 63 healthy normolipidemic individuals taken as controls...
December 20, 2016: Comptes Rendus Biologies
https://www.readbyqxmd.com/read/27999056/switching-from-a-ritonavir-boosted-pi-to-dolutegravir-as-an-alternative-strategy-in-virologically-suppressed-hiv-infected-individuals
#4
Eugènia Negredo, Vicente Estrada, Pere Domingo, Maria Del Mar Gutiérrez, Gracia M Mateo, Jordi Puig, Anna Bonjoch, Arelly Ornelas, Patricia Echeverría, Carla Estany, Jessica Toro, Bonaventura Clotet
BACKGROUND: Switching from PIs to dolutegravir in virologically suppressed HIV-infected individuals has not been assessed. OBJECTIVES: The principal aim was to assess the evolution of bone mineral density (BMD) when switching from a ritonavir-boosted PI to dolutegravir in HIV-infected patients with osteopenia or osteoporosis. The secondary objective was to assess the antiviral efficacy and safety of the switch therapy. METHODS: This randomized, multicentre study assessed changes in BMD, bone turnover markers, and antiviral efficacy and safety in 73 virologically suppressed patients with osteopenia/osteoporosis taking a ritonavir-boosted PI plus abacavir/lamivudine who were randomized to switch from PI to dolutegravir (DOLU group, n = 37) or continue with a PI (PI group, n = 36)...
December 20, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27979047/statin-therapy-and-low-density-lipoprotein-cholesterol-reduction-in-hiv-infected-individuals-after-acute-coronary-syndrome-results-from-the-pacs-hiv-lipids-substudy
#5
Franck Boccara, Joe Miantezila Basilua, Murielle Mary-Krause, Sylvie Lang, Emmanuel Teiger, Philippe Gabriel Steg, Christian Funck-Brentano, Pierre-Marie Girard, Dominique Costagliola, Ariel Cohen, Marguerite Guiguet
: Knowledge about lipid interventions in secondary prevention in HIV-infected individuals is limited; studies are sparse. METHODS: A prospective observational multicenter study enrolled 282 patients on statin 1 month after first acute coronary syndrome (ACS) (95 HIV-infected individuals, 187 HIV-uninfected). Data on fasting lipids (total cholesterol [TC], low-density lipoprotein cholesterol, high-density lipoprotein cholesterol [HDL-C], non-HDL-C, triglycerides, TC/HDL-C ratio) were collected over 3 years...
January 2017: American Heart Journal
https://www.readbyqxmd.com/read/27956833/inflammation-modulating-cytokine-profile-and-lipid-interaction-in-hiv-related-risk-factors-for-cardiovascular-diseases
#6
Elizabeth Gori, Takafira Mduluza, Mudavanhu Nyagura, Babill Stray-Pedersen, Zvenyika Alfred Gomo
HIV infection and antiretroviral therapy (ART) are associated with changes in plasma levels of lipoproteins, thus posing the risk of cardiovascular complications in infected individuals. The alteration in plasma lipoprotein levels results from dysregulation of inflammation-modulating cytokines that control lipid metabolism. Little is understood regarding the relationship between the cytokines and serum lipid levels, which have been reported to be altered in adults receiving ART. The objective of this study was to describe the profiles of inflammation-modulating cytokines and their relationship to lipids as cardiovascular disease (CVD) risk factors in HIV infection...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/27951755/comparative-effectiveness-of-tenofovir-in-hiv-infected-treatment-experienced-patients-systematic-review-and-meta-analysis
#7
Hannah Ewald, Marilia Santini-Oliveira, Julian-Emanuel Bühler, Danielle Vuichard, Stefan Schandelmaier, Marcel Stöckle, Matthias Briel, Heiner C Bucher, Lars G Hemkens
BACKGROUND: Antiretroviral therapy (ART) regimens for HIV infection are frequently changed. We conducted a systematic review of randomized trials (RCTs) on the benefits and harms of switching to tenofovir disoproxil fumarate (TDF)-based regimens in ART-experienced patients. METHODS: We included RCTs in HIV-infected adults comparing switching to a TDF-containing regimen with maintaining or switching to another regimen. We searched MEDLINE, EMBASE, CENTRAL, LILACS, SCI, and the WHO Global Health Library...
January 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/27904105/evaluation-of-the-lipid-concentrations-after-switching-from-antiretroviral-drug-tenofovir-disoproxil-fumarate-emtricitabine-to-abacavir-sulfate-lamivudine-in-virologically-suppressed-human-immunodeficiency-virus-infected-patients
#8
Hirotaka Arae, Masao Tateyama, Hideta Nakamura, Daisuke Tasato, Kaoru Kami, Kyoko Miyagi, Saori Maeda, Hitoshi Uehara, Makiko Moromi, Katsunori Nakamura, Jiro Fujita
Objective Recently, tenofovir disoproxil fumatate (TDF)-related side effects, such as renal nephrotoxicity and reduction of bone mineral density, have been reported. Consequently, increased switching from fixed-dose tablet TDF and emtricitabine (TDF/FTC) to abacavir and lamivudine (ABC/3TC) has occurred. Interestingly, while TDF has a lipid-lowering property, one of the ABC-related side effects is hyperlipidemia. Therefore, such switching could cause lipid elevation. To evaluate the change in lipid levels associated with switching from TDF/FTC to ABC/3TC in virologically-suppressed human immunodeficiency virus (HIV)-infected patients...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27864732/impact-of-pharmaceutical-care-on-cardiovascular-risk-among-older-hiv-patients-on-antiretroviral-therapy
#9
Elza Aparecida Machado Domingues, Mónica Ferrit-Martín, Miguel Ángel Calleja-Hernández
Background Advances in the treatment of HIV infection have enabled better control of the disease, allowing patients to enjoy a longer life expectancy. However, the ageing of patients leads to an increased prevalence of cardiovascular disease. Various studies have found that pharmaceutical care results in better control of cardiovascular risk factors. Objective To measure the impact of pharmaceutical care on cardiovascular risk in patients older than 50 years receiving combination antiretroviral therapy. Setting Outpatient pharmacy service of a tertiary hospital, Spain...
February 2017: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/27822124/changes-in-coronary-heart-disease-risk-profiles-of-hiv-patients-in-zimbabwe-over-9-months-a-follow-up-study
#10
Danai Tavonga Zhou, Olav Oektedalen, Sandra Shawarira-Bote, Babill Stray-Pedersen
Dyslipidemia, hypertension, inflammation, and coronary heart disease (CHD) are adverse events in human immunodeficiency virus (HIV)-infected patients even if they are receiving antiretroviral therapy (ART). Yet, data on CHD risk induced by HIV or ART in sub-Saharan Africa are limited. The aim of this longitudinal study was to describe changes in CHD risk profiles measured by lipids, inflammatory markers, and Framingham scores among HIV-positive patients previously reported from Harare, Zimbabwe. Patients were grouped into ART-experienced patients (n=147) and ART-naïve patients (n=23) and followed up for 9 months...
2016: HIV/AIDS: Research and Palliative Care
https://www.readbyqxmd.com/read/27759575/changes-in-urinary-biomarkers-over-10-years-is-associated-with-viral-suppression-in-a-prospective-cohort-of-women-living-with-hiv
#11
Sanjiv M Baxi, Rebecca Scherzer, Vasantha Jotwani, Michelle M Estrella, Alison G Abraham, Chirag R Parikh, Michael R Bennett, Mardge H Cohen, Marek J Nowicki, Deborah R Gustafson, Anjali Sharma, Mary A Young, Michael G Shlipak
BACKGROUND: Urine biomarkers have helped identify persons at risk for progressing to kidney disease in the setting of HIV infection. We explored factors associated with changes in three urine biomarkers over 10 years among women living with HIV. METHODS: Prospective cohort of 294 HIV-infected women from the multicenter Women's Interagency HIV Study (WIHS). Predictors included HIV viral and immunological parameters, co-morbid conditions and health-related behaviors...
October 18, 2016: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/27753678/statin-drugs-decrease-progression-to-cirrhosis-in-hiv-hepatitis-c-virus-coinfected-individuals
#12
Nora T Oliver, Christine M Hartman, Jennifer R Kramer, Elizabeth Y Chiao
INTRODUCTION: Chronic HIV/hepatitis C virus (HCV) coinfection carries increased risk of cirrhosis, hepatocellular carcinoma, and death. Due to anti-inflammatory properties, 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) inhibitors (statins) may be useful adjunctive therapy to reduce liver disease progression. METHODS: Clinical information was extracted from the Veterans Affairs HIV and HCV Clinical Case Registries (1999-2010). HIV-related variables included combination antiretroviral therapy era of diagnosis, CD4 cell count, and percentage time with undetectable HIV viral load...
October 23, 2016: AIDS
https://www.readbyqxmd.com/read/27749649/safety-and-efficacy-of-atorvastatin-in-human-immunodeficiency-virus-infected-children-adolescents-and-young-adults-with-hyperlipidemia
#13
Ann J Melvin, Grace Montepiedra, Lisa Aaron, William A Meyer, Hans M Spiegel, William Borkowsky, Mark J Abzug, Brookie M Best, Marilyn J Crain, Peggy R Borum, Bobbie Graham, Patricia Anthony, Katherine Shin, George K Siberry
BACKGROUND: Human immunodeficiency virus (HIV)-infected children receiving antiretroviral therapy (ART) have increased prevalence of hyperlipidemia and risk factors for cardiovascular disease. No studies have investigated the efficacy and safety of statins in this population. METHODS: HIV-infected youth 10 to <24 years of age on stable ART with low-density lipoprotein cholesterol (LDL-C) ≥130 mg/dL for ≥6 months initiated atorvastatin 10 mg once daily...
January 2017: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27740536/treatment-of-hiv-infection-with-a-raltegravir-based-regimen-increases-ldl-levels-but-improves-hdl-cholesterol-efflux-capacity
#14
Nicholas T Funderburg, Dihua Xu, Martin P Playford, Aditya A Joshi, Adriana Andrade, Daniel R Kuritzkes, Michael M Lederman, Nehal N Mehta
BACKGROUND: Persons infected with HIV often have altered lipid profiles that may be affected by antiretroviral therapies (ART). Traditional lipid measurements may be insufficient to assess cardiovascular disease (CVD) risk in this population. METHODS: We report results from 39 ART-naive participants in a substudy of A5248, a single-arm study of raltegravir, emtricitabine/tenofovir administration. Samples were collected at baseline, 12, 24 and 48 weeks after ART initiation...
October 14, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27727770/hdl-cholesterol-as-a-predictor-of-cd4-count-in-hiv-infected-patients-taking-nnrti-based-haart-regimen-at-tertiary-care-art-centre-in-mysore
#15
Soumya K, Rangaswamy
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27603338/high-density-lipoprotein-cholesterol-levels-and-risk-of-cancer-in-hiv-infected-subjects-data-from-the-icona-foundation-cohort
#16
Nicola Squillace, Laura Galli, Alessandra Bandera, Antonella Castagna, Giordano Madeddu, Pietro Caramello, Andrea Antinori, Annamaria Cattelan, Franco Maggiolo, Antonella Cingolani, Andrea Gori, Antonella d'Arminio Monforte
Investigation of the relationship between high-density lipoprotein-cholesterol (HDL-c) and the risk of developing cancer in a prospective cohort of human immunodeficiency virus (HIV)-infected patients.The Italian Cohort of Antiretroviral-naïve Patients Foundation Cohort is an Italian multicenter observational study recruiting HIV-positive patients while still antiretroviral treatment-naïve, regardless of the reason since 1997.Patients with at least 1 HDL-c value per year since enrollment and one such value before antiretroviral treatment initiation were included...
September 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27600391/lipids-profile-among-art-na%C3%A3-ve-hiv-infected-patients-and-men-who-have-sex-with-men-in-china-a-case-control-study
#17
Qi Wang, Haibo Ding, Junjie Xu, Wenqing Geng, Jing Liu, Xiaolin Guo, Jing Kang, Xiaolin Li, Yongjun Jiang, Hong Shang
BACKGROUND: Dyslipidemia is commonly seen in human immunodeficiency virus (HIV) infected patients. Understanding the risk factors of abnormal lipid profiles is urgent for proposing targeted approaches to prevention. Our objective was to assess the incidence and associated factors of abnormal lipid profiles and atherogenic index of plasma (AIP) among antiretroviral therapy (ART) naïve men who have sex with men (MSM) acute HIV infection (AHI) and chronic HIV infection (CHI) patients in China...
September 6, 2016: Lipids in Health and Disease
https://www.readbyqxmd.com/read/27591292/effectiveness-and-safety-of-an-abacavir-lamivudine%C3%A2-%C3%A2-rilpivirine-regimen-for-the-treatment-of-hiv-1-infection-in-naive-patients
#18
Adrian Curran, Jhon Rojas, Alfonso Cabello, Jesús Troya, Arkaitz Imaz, Pere Domingo, Esteban Martinez, Pablo Ryan, Miguel Górgolas, Daniel Podzamczer, Hernando Knobel, Félix Gutiérrez, Esteban Ribera
OBJECTIVES: To describe the effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen in naive HIV-1-infected patients, as there is a lack of data with this combination. METHODS: This was an observational, retrospective, multicentre study in eight Spanish hospitals. All antiretroviral-naive patients ≥18 years old and starting abacavir/lamivudine + rilpivirine were included. Effectiveness (ITT and on-treatment) and safety (adverse events and laboratory parameters) were assessed during follow-up...
September 2, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27579612/dyslipidemias-and-elevated-cardiovascular-risk-on-lopinavir-based-antiretroviral-therapy-in-cambodia
#19
Setha Limsreng, Olivier Marcy, Sowath Ly, Vara Ouk, Hak Chanroeurn, Saem Thavary, Ban Boroath, Ana Canestri, Gérald Viretto, Jean-François Delfraissy, Olivier Ségéral
BACKGROUND: Lopinavir/ritonavir (LPV/r) is widely used in Cambodia with high efficacy but scarce data exist on long-term metabolic toxicity. METHODS: We carried out a cross-sectional and retrospective study evaluating metabolic disorders and cardiovascular risk in Cambodian patients on LPV/r-based antiretroviral therapy (ART) for > 1 year followed in Calmette Hospital, Phnom Penh. Data collected included cardiovascular risk factors, fasting blood lipids and glucose, and retrospective collection of bioclinical data...
2016: PloS One
https://www.readbyqxmd.com/read/27570910/association-of-dyslipidemia-and-glucose-abnormalities-with-antiretroviral-treatment-in-a-cohort-of-hiv-infected-latin-american-children
#20
Machline P Paganella, Rachel A Cohen, Donald R Harris, Ricardo de Souza Kuchenbecker, Rosa D Sperhacke, Sergio K Kato, Carmem L Oliveira da Silva, Fernanda T Sturzbecher, Ricardo H S Oliveira, Noris Pavía-Ruz, Rohan Hazra
OBJECTIVE: To estimate the incidence of lipid and glucose abnormalities and assess their association with exposure to antiretroviral (ARV) regimens among perinatally HIV-infected Latin American children. DESIGN: Longitudinal cohort study. METHODS: Data were analyzed from the Eunice Kennedy Shriver National Institute of Child Health and Human Development International Site Development Initiative Pediatric Latin American Countries Epidemiologic Study...
January 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
keyword
keyword
30100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"